Arcutis Biotherapeutics, Inc. (ARQT) Guidance & Earnings Results
On 2026-08-05 Arcutis Biotherapeutics, Inc. raised guidance: "Full-year 2026 net product sales guidance raised to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARQTArcutis Biotherapeutics, Inc.Follow ARQT — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- 148.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Raised | Full-year 2026 net product sales guidance raised to $525M-$540M · full year |
| 25 Feb 26 | Raised | FY2026 net product sales guidance raised to $480M-$495M · full year |
| 28 Oct 25 | Raised | Initial 2026 guidance: net product revenue $455M-$470M · full year |
Arcutis Biotherapeutics, Inc. — questions
- What guidance did Arcutis Biotherapeutics, Inc. give?
- On 2026-08-05: "Full-year 2026 net product sales guidance raised to $525M-$540M"
- When does Arcutis Biotherapeutics, Inc. report earnings?
- Arcutis Biotherapeutics, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Arcutis Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.